Close

China’s Experimental COVID-19 Vaccine Appears Safe In Early Trials Study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

COVID-19 Vaccine: In a Phase 1 trial of 191 healthy participants aged between 18 and 59, vaccination with the group’s experimental shot showed no severe adverse reactions, its COVID-19 Vaccine: In a Phase 1 trial of 191 healthy participants aged between 18 and 59, vaccination with the group’s experimental shot showed no severe adverse reactions, its researchers said.

A Chinese experimental coronavirus vaccine being developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences was shown to be safe in an early stage clinical trial, researchers said.

In a Phase 1 trial of 191 healthy participants aged between 18 and 59, vaccination with the group’s experimental shot showed no severe adverse reactions, its researchers said on Tuesday in a paper posted on medRxiv preprint server ahead of peer review.

The most common adverse reactions reported by the trial participants were mild pain, slight fatigue and redness, itching and swelling at the injection site.

“All the data obtained in this trial support the safety and immunogenicity of this inactivated vaccine and are encouraging with regard to further studies of its efficacy in the future,” the paper said.

China has inoculated hundreds of thousands of essential workers and other groups considered at high risk with other vaccines, even as clinical trials had not been fully completed, raising safety concerns among experts.

Latest stories

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back